Recombinant Human Notch2 (C-6His)

Description

EnkiLife provides the Recombinant Human Notch2 (C-6His) protein,aslo know as AGS2,hN2,Notch homolog 2,Notch2,Notch-2,HJCYS, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Neurogenic Locus Notch Homolog Protein 2 is produced by our Mammalian expression system and the target gene encoding Leu26-Gln530 is expressed with a 6His tag at the C-terminus.Accession:Q04721. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:54.9 KDa. Background:Notch-2 is a 300 kDa type I transmembrane glycoprotein that is one of four human Notch homologues involved in developmental processes. Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Human Notch-2 ECD (aa 26-530) shows 93%, 93%, 96% and 96% aa identity with the corresponding regions of mouse, rat, canine, and bovine Notch-2, respectively. Hajdu Cheney Syndrome (HCS) is a rare disease associated with mutations of NOTCH2 that lead to the translation of a truncated, presumably stable, NOTCH2 protein. NOTCH2 is down-regulated in colon cancer, and reduced expression is associated with a less differentiated, more aggressive phenotype, and reduced overall survival. NOTCH2 has also been shown to have pro-apoptotic and growth suppressive effects in thyroid carcinoma, and carcinoid tumors. NOTCH2 acts as an oncogene that promotes bladder cancer growth and metastasis through EMT, cell-cycle progression, and maintenance of stemness.